Cargando…
The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome
Limited evidence exists to guide the management of recurrent thrombosis occurring despite therapeutic anticoagulation in patients with thrombotic antiphospholipid syndrome (APS). In this case series, fondaparinux, with or without an antiplatelet agent, provided an effective and safe option in three...
Autores principales: | Sayar, Zara, Burke, Shoshana, Mittal, Prabal, Cohen, Hannah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580031/ https://www.ncbi.nlm.nih.gov/pubmed/36074077 http://dx.doi.org/10.1177/09612033221122147 |
Ejemplares similares
-
Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management
por: Sayar, Zara, et al.
Publicado: (2021) -
Recurrent Nonbacterial Thrombotic Endocarditis and Primary Antiphospholipid Antibody Syndrome
por: Mandal, Amit K, et al.
Publicado: (2023) -
The Effect of Rituximab on Antiphospholipid Titers in Patients with Antiphospholipid Syndrome
por: Youkhana, Kimberley, et al.
Publicado: (2023) -
Clinical Management of Thrombotic Antiphospholipid Syndrome
por: Tumian, Nor Rafeah, et al.
Publicado: (2022) -
Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome
por: Zhou, Zhuochao, et al.
Publicado: (2021)